Comparing SG&A Expenses: Alkermes plc vs Alpine Immune Sciences, Inc. Trends and Insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Alkermes plc and Alpine Immune Sciences, Inc., from 2014 to 2023.

Alkermes plc: A Steady Climb

Alkermes plc has shown a consistent upward trend in SG&A expenses, starting at approximately $200 million in 2014 and reaching nearly $690 million by 2023. This represents a staggering 245% increase over the decade, reflecting the company's expanding operations and market reach.

Alpine Immune Sciences, Inc.: A Modest Rise

In contrast, Alpine Immune Sciences, Inc. began with SG&A expenses of around $2.3 million in 2014, growing to about $22 million in 2023. This tenfold increase highlights the company's strategic investments in administrative capabilities as it scales its operations.

These trends underscore the differing growth trajectories and strategic priorities of these two biotech firms, offering valuable insights into their financial management strategies.